-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hurry up and put these guidelines/consensus in your bag! As 2022 is approaching, Jie Xiaomi has specially launched the annual high-quality guide/consensus compilation to lead readers to take a closer look
.
This compilation is introduced in the order of publication in the section content, and contains guidelines/consensus that are titled the 2020 edition but will not be officially published until 2021
.
Diabetes: 1 "Guidelines for Diagnosis and Treatment of Diabetes in the Elderly in China (2021 Edition)" As China's aging has intensified, the prevalence of diabetes in the elderly has also increased significantly
.
According to data in 2019, the number of elderly diabetic patients in China ranks first in the world, and there is an urgent need for standardized management of elderly diabetic patients
.
In January this year, China’s first "Guidelines for Diagnosis and Treatment of Diabetes in the Elderly in China (2021 Edition)" (hereinafter referred to as "Guidelines") was officially released.
Or) The characteristics of multiple diseases, atypical symptoms, high risk of hypoglycemia, and poor self-management ability of patients provide individualized management strategies and provide strong guidance and suggestions for the standardized clinical treatment of elderly type 2 diabetes patients
.
To see the detailed guideline interpretation, please click on the link below 👇: 1.
The first "Guidelines for Diagnosis and Treatment of Diabetes in the Elderly in China (2021 Edition)" is released.
The treatment of elderly diabetes is well-founded! 2.
Geriatric diabetes management: look at what the first Chinese guide says 4 "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)" After three years, the Diabetes Association of the Chinese Medical Association released the 6th edition of "China Type 2" in April this year.
Diabetes Prevention Guidelines (2020 Edition)" (hereinafter referred to as "Guide")
.
The guide has 19 chapters, covering the epidemiology of diabetes in China, the diagnosis and classification of diabetes, the screening and evaluation of diabetes, the comprehensive control goals of type 2 diabetes and the treatment path of hyperglycemia, the drug treatment of hyperglycemia, acute diabetes and diabetes chronic complications, such as hypoglycemia
.
To see the detailed guideline interpretation, please click the link below 👇: 1.
The full text of the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" has finally been released, and the top 10 update points are here! A quick overview of the article 2.
How to manage the 7 major complications of diabetes? Comparing the 2017 edition to interpret the 2020CDS guideline 6 "Experts Consensus on Diabetic Neuropathy Diagnosis and Treatment (2021 Edition)" Diabetic neuropathy is a group of clinical syndromes with diversified manifestations due to different pathophysiological mechanisms.
It is the most common type of type 1 and type 2 diabetes.
One of the common chronic complications, about 50% of diabetic patients will eventually develop distal symmetrical polyneuropathy (DSPN)
.
In order to effectively delay disease progression and regulate management of diabetic peripheral neuropathy, the "Expert Consensus on Diabetic Neuropathy (2021 Edition)" was officially released in June this year.
The "Consensus" introduced diabetic neuropathy (mainly distal symmetrical multiple Epidemiology, pathogenesis, classification, screening and diagnosis, prevention and treatment of sexual neuropathy and autonomic neuropathy
.
To see the detailed consensus interpretation, please click the link below 👇: How to manage diabetic neuropathy that causes headaches for doctors and patients? The latest expert consensus is here! 8 "Guidelines for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 Edition)" Diabetic nephropathy (DKD) is a common chronic complication of diabetes and one of the important causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD)
.
Therefore, the standardized diagnosis and treatment of DKD has become a topic of great concern in the fields of kidney disease and endocrinology at home and abroad
.
Based on new research evidence, the Microvascular Complications Group of the Diabetes Branch of the Chinese Medical Association organized national endocrinology and nephropathy experts to compile the "Guidelines for the Prevention and Treatment of Diabetic Nephropathy in China (2021 Edition)", which was officially released in August this year
.
The content covered by this guide highlights the importance of early screening, pays attention to the role of new anti-hyperglycemic drugs in the treatment of DKD, and also emphasizes the integrated diagnosis and treatment model of “diagnosis-typing-evaluation-prevention”, highlighting clinical practicality Sex
.
The guidelines will help clinicians conduct standardized management of DKD patients and are committed to improving the prognosis of DKD patients
.
For this guide, we mainly interpret the early screening, diagnosis, staging, prognostic evaluation and prevention of DKD
.
To see the detailed guideline interpretation, please click the link below 👇: "Guidelines for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 Edition)" released: new evidence, opening a new era of integrated diagnosis and treatment! 9 "Consensus of Chinese Experts on Alleviating Type 2 Diabetes" In recent years, a large number of clinical scientific research results have shown that for overweight and obese type 2 diabetes (T2DM) patients, it is possible to intervene through diet, exercise, behavioral intervention, drug therapy, and metabolic surgery.
A variety of methods, so as to achieve effective control of blood sugar in a long period of time without the use of hypoglycemic drugs
.
In order to help Chinese clinicians to standardize the clinical treatment of T2DM alleviation in overweight or obese T2DM patients, so that patients can obtain safe and effective intervention measures, in September this year, the "China Expert Consensus on Alleviating Type 2 Diabetes" was officially launched
.
We mainly interpret this consensus from the definition, conditions, and mitigation methods of T2DM mitigation
.
To see the detailed consensus interpretation, please click the link below 👇: China's first expert consensus on relieving type 2 diabetes is released! Come and watch! 10 "Consensus of Chinese Experts on the Diagnosis and Treatment of Latent Autoimmune Diabetes in Adults (2021 Edition)" Latent Autoimmune Diabetes in Adults (LADA) is a type of diabetes caused by slow autoimmune damage to pancreatic islet cells
.
In recent years, as domestic and foreign researchers have deepened their understanding of LADA research, as with other diseases, the clinical diagnostic criteria and new treatment methods for LADA have been gradually improved and improved
.
In order to convey the latest important clinical progress and better guide the clinical practice of relevant departments, in October this year, the "Chinese Expert Consensus on the Diagnosis and Treatment of Adult Occult Autoimmune Diabetes (2021 Edition)" came into being
.
We interpreted this consensus from the aspects of LADA epidemiology, genetics, immunological characteristics, clinical manifestations, diagnosis and typing, treatment and management
.
To see the detailed consensus interpretation, please click the link below 👇: After 9 years, China’s LADA diagnosis and treatment consensus has been updated again! Take a look at the key points 11 "Experts Consensus on Short-term Intensive Insulin Therapy Reversing Type 2 Diabetes" With the continuous deepening of modern medical research, diabetes has gradually begun to get rid of the hat of "lifelong disease"
.
The latest medical concept believes that type 2 diabetes (T2DM) is reversible in the early stages
.
In November this year, the "Expert Consensus on Short-term Intensive Insulin Therapy Reversing Type 2 Diabetes" was published in the Chinese Journal of Diabetes.
The consensus pointed out that short-term intensive insulin therapy (SIIT) can significantly improve pancreatic β-cell function and insulin sensitivity.
An effective means to reverse T2DM
.
So, what is the definition of reversal of T2DM? Which T2DM patients can be reversed by SIIT? The following consensus interpretation will bring you the answer! (Later we will launch a video course to analyze the specific clinical practice in detail, so stay tuned!) To see the detailed consensus interpretation, please click the link below 👇: "Reverse" Type 2 Diabetes, endocrinologists provide this guide! 12 "2022 ADA Diabetes Medical Diagnosis and Treatment Standards" A few days ago, the American Diabetes Association (ADA) released the latest version of the Diabetes Diagnosis and Treatment Standards for 2022.
Based on the latest diabetes scientific research and clinical trials, this guideline is updated from the original 16 chapters to Seventeen, covering the diagnosis and treatment of patients with type 1, type 2 or gestational diabetes, as well as comprehensive health management of complications
.
There is another surprising point in this guideline update.
"The recommended content for first-line treatment and initial treatment is no longer based on metformin as the absolute initial drug of choice for patients with type 2 diabetes, but recommended based on comorbidities, Patient-centered treatment factors and management needs to choose
.
"If you want to see the detailed interpretation of diagnosis and treatment standards, please click the link below 👇: 2022 ADA guide update: Metformin's "initial first choice" status is shaken? Obesity: 11 "Clinical-based Obesity Multidisciplinary Diagnosis and Treatment Consensus" The current domestic and foreign expert consensus on obesity is mostly single-disciplinary or dual-disciplinary consensus, and it focuses on nutrition and surgical operations
.
Based on this situation, China has released the first multidisciplinary consensus on obesity-"Clinical-based Multidisciplinary Consensus on Obesity Diagnosis and Treatment" (hereinafter referred to as "Consensus")
.
The "Consensus" mainly includes: obesity epidemiology and pathogenesis, obesity diagnosis and evaluation, clinical intervention and management of obesity, and disease-centric obesity centralized management
.
Through the above four parts, update and optimize the concept of diagnosis and treatment of obesity, in order to reduce the current clinical bias in the diagnosis and treatment of the disease
.
To see the detailed consensus interpretation, please click the link below 👇: Chinese adults are "half fat"! In addition to keeping your mouth open and opening your legs, you also have to know these osteoporosis articles: 5 "Expert Consensus on the Diagnosis and Treatment of Osteoporosis in Primary Medical Institutions (2021)" Osteoporosis is a common type of bone disease in clinical practice.
It is A systemic bone disease characterized by decreased bone mass and destruction of bone tissue microstructure, resulting in increased bone fragility and prone to fractures
.
Because its disease generally has no obvious characteristics, and the degree of clinical diagnosis and treatment is not high, patients often find that they have osteoporosis when they have a fracture.
Therefore, osteoporosis is also called a "quiet killer"
.
Based on this situation, the "Experts Consensus on the Diagnosis and Treatment of Osteoporosis in Primary Medical Institutions (2021)" was officially published in May this year.
Primary medical service institutions, as the most suitable medical institutions for early prevention and treatment of osteoporosis, should have a more unified The prevention and management model and practical and effective guidance standards
.
For this consensus, we mainly introduced the six aspects of osteoporosis screening tools, identification of high-risk groups, clinical diagnosis, treatment goals, prevention and management
.
To see the detailed consensus interpretation, please click the link below 👇: How do the grassroots deal with osteoporosis? Expert consensus is here! Gout: 12 "Gout Treatment Clinical Practice Guidelines in 2021" (APLAR) In recent years, the prevalence of gout has gradually increased in the Asia-Pacific region and even the world
.
According to statistics for 2020, there are more than 80 million people suffering from gout in China, making it the second largest metabolic disease after diabetes
.
In order to better implement standardized treatment of gout and provide clinical medical workers with a basis for diagnosis and treatment decision-making, in December this year, the Asia-Pacific Anti-Rheumatic Alliance (APLAR) released the 2021 clinical practice guidelines for gout treatment, aiming to provide evidence based on existing evidence.
Provide advice on the management of different stages of gout
.
We focused on the interpretation of the guidelines from important issues in gout management such as diet and weight management, non-drug treatment, asymptomatic hyperuricemia treatment, and anti-inflammatory treatment in the acute phase of gout
.
To see the detailed guideline interpretation, please click the link below 👇: Regarding gout, the 18 latest recommendations of clinical practice guidelines are here! Which of the above guidelines/consensus are you most interested in? What other guidelines/consensus interpretations of endocrine diseases do you want to see in the future? Welcome to leave a message at the bottom of the article!
.
This compilation is introduced in the order of publication in the section content, and contains guidelines/consensus that are titled the 2020 edition but will not be officially published until 2021
.
Diabetes: 1 "Guidelines for Diagnosis and Treatment of Diabetes in the Elderly in China (2021 Edition)" As China's aging has intensified, the prevalence of diabetes in the elderly has also increased significantly
.
According to data in 2019, the number of elderly diabetic patients in China ranks first in the world, and there is an urgent need for standardized management of elderly diabetic patients
.
In January this year, China’s first "Guidelines for Diagnosis and Treatment of Diabetes in the Elderly in China (2021 Edition)" (hereinafter referred to as "Guidelines") was officially released.
Or) The characteristics of multiple diseases, atypical symptoms, high risk of hypoglycemia, and poor self-management ability of patients provide individualized management strategies and provide strong guidance and suggestions for the standardized clinical treatment of elderly type 2 diabetes patients
.
To see the detailed guideline interpretation, please click on the link below 👇: 1.
The first "Guidelines for Diagnosis and Treatment of Diabetes in the Elderly in China (2021 Edition)" is released.
The treatment of elderly diabetes is well-founded! 2.
Geriatric diabetes management: look at what the first Chinese guide says 4 "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)" After three years, the Diabetes Association of the Chinese Medical Association released the 6th edition of "China Type 2" in April this year.
Diabetes Prevention Guidelines (2020 Edition)" (hereinafter referred to as "Guide")
.
The guide has 19 chapters, covering the epidemiology of diabetes in China, the diagnosis and classification of diabetes, the screening and evaluation of diabetes, the comprehensive control goals of type 2 diabetes and the treatment path of hyperglycemia, the drug treatment of hyperglycemia, acute diabetes and diabetes chronic complications, such as hypoglycemia
.
To see the detailed guideline interpretation, please click the link below 👇: 1.
The full text of the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" has finally been released, and the top 10 update points are here! A quick overview of the article 2.
How to manage the 7 major complications of diabetes? Comparing the 2017 edition to interpret the 2020CDS guideline 6 "Experts Consensus on Diabetic Neuropathy Diagnosis and Treatment (2021 Edition)" Diabetic neuropathy is a group of clinical syndromes with diversified manifestations due to different pathophysiological mechanisms.
It is the most common type of type 1 and type 2 diabetes.
One of the common chronic complications, about 50% of diabetic patients will eventually develop distal symmetrical polyneuropathy (DSPN)
.
In order to effectively delay disease progression and regulate management of diabetic peripheral neuropathy, the "Expert Consensus on Diabetic Neuropathy (2021 Edition)" was officially released in June this year.
The "Consensus" introduced diabetic neuropathy (mainly distal symmetrical multiple Epidemiology, pathogenesis, classification, screening and diagnosis, prevention and treatment of sexual neuropathy and autonomic neuropathy
.
To see the detailed consensus interpretation, please click the link below 👇: How to manage diabetic neuropathy that causes headaches for doctors and patients? The latest expert consensus is here! 8 "Guidelines for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 Edition)" Diabetic nephropathy (DKD) is a common chronic complication of diabetes and one of the important causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD)
.
Therefore, the standardized diagnosis and treatment of DKD has become a topic of great concern in the fields of kidney disease and endocrinology at home and abroad
.
Based on new research evidence, the Microvascular Complications Group of the Diabetes Branch of the Chinese Medical Association organized national endocrinology and nephropathy experts to compile the "Guidelines for the Prevention and Treatment of Diabetic Nephropathy in China (2021 Edition)", which was officially released in August this year
.
The content covered by this guide highlights the importance of early screening, pays attention to the role of new anti-hyperglycemic drugs in the treatment of DKD, and also emphasizes the integrated diagnosis and treatment model of “diagnosis-typing-evaluation-prevention”, highlighting clinical practicality Sex
.
The guidelines will help clinicians conduct standardized management of DKD patients and are committed to improving the prognosis of DKD patients
.
For this guide, we mainly interpret the early screening, diagnosis, staging, prognostic evaluation and prevention of DKD
.
To see the detailed guideline interpretation, please click the link below 👇: "Guidelines for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 Edition)" released: new evidence, opening a new era of integrated diagnosis and treatment! 9 "Consensus of Chinese Experts on Alleviating Type 2 Diabetes" In recent years, a large number of clinical scientific research results have shown that for overweight and obese type 2 diabetes (T2DM) patients, it is possible to intervene through diet, exercise, behavioral intervention, drug therapy, and metabolic surgery.
A variety of methods, so as to achieve effective control of blood sugar in a long period of time without the use of hypoglycemic drugs
.
In order to help Chinese clinicians to standardize the clinical treatment of T2DM alleviation in overweight or obese T2DM patients, so that patients can obtain safe and effective intervention measures, in September this year, the "China Expert Consensus on Alleviating Type 2 Diabetes" was officially launched
.
We mainly interpret this consensus from the definition, conditions, and mitigation methods of T2DM mitigation
.
To see the detailed consensus interpretation, please click the link below 👇: China's first expert consensus on relieving type 2 diabetes is released! Come and watch! 10 "Consensus of Chinese Experts on the Diagnosis and Treatment of Latent Autoimmune Diabetes in Adults (2021 Edition)" Latent Autoimmune Diabetes in Adults (LADA) is a type of diabetes caused by slow autoimmune damage to pancreatic islet cells
.
In recent years, as domestic and foreign researchers have deepened their understanding of LADA research, as with other diseases, the clinical diagnostic criteria and new treatment methods for LADA have been gradually improved and improved
.
In order to convey the latest important clinical progress and better guide the clinical practice of relevant departments, in October this year, the "Chinese Expert Consensus on the Diagnosis and Treatment of Adult Occult Autoimmune Diabetes (2021 Edition)" came into being
.
We interpreted this consensus from the aspects of LADA epidemiology, genetics, immunological characteristics, clinical manifestations, diagnosis and typing, treatment and management
.
To see the detailed consensus interpretation, please click the link below 👇: After 9 years, China’s LADA diagnosis and treatment consensus has been updated again! Take a look at the key points 11 "Experts Consensus on Short-term Intensive Insulin Therapy Reversing Type 2 Diabetes" With the continuous deepening of modern medical research, diabetes has gradually begun to get rid of the hat of "lifelong disease"
.
The latest medical concept believes that type 2 diabetes (T2DM) is reversible in the early stages
.
In November this year, the "Expert Consensus on Short-term Intensive Insulin Therapy Reversing Type 2 Diabetes" was published in the Chinese Journal of Diabetes.
The consensus pointed out that short-term intensive insulin therapy (SIIT) can significantly improve pancreatic β-cell function and insulin sensitivity.
An effective means to reverse T2DM
.
So, what is the definition of reversal of T2DM? Which T2DM patients can be reversed by SIIT? The following consensus interpretation will bring you the answer! (Later we will launch a video course to analyze the specific clinical practice in detail, so stay tuned!) To see the detailed consensus interpretation, please click the link below 👇: "Reverse" Type 2 Diabetes, endocrinologists provide this guide! 12 "2022 ADA Diabetes Medical Diagnosis and Treatment Standards" A few days ago, the American Diabetes Association (ADA) released the latest version of the Diabetes Diagnosis and Treatment Standards for 2022.
Based on the latest diabetes scientific research and clinical trials, this guideline is updated from the original 16 chapters to Seventeen, covering the diagnosis and treatment of patients with type 1, type 2 or gestational diabetes, as well as comprehensive health management of complications
.
There is another surprising point in this guideline update.
"The recommended content for first-line treatment and initial treatment is no longer based on metformin as the absolute initial drug of choice for patients with type 2 diabetes, but recommended based on comorbidities, Patient-centered treatment factors and management needs to choose
.
"If you want to see the detailed interpretation of diagnosis and treatment standards, please click the link below 👇: 2022 ADA guide update: Metformin's "initial first choice" status is shaken? Obesity: 11 "Clinical-based Obesity Multidisciplinary Diagnosis and Treatment Consensus" The current domestic and foreign expert consensus on obesity is mostly single-disciplinary or dual-disciplinary consensus, and it focuses on nutrition and surgical operations
.
Based on this situation, China has released the first multidisciplinary consensus on obesity-"Clinical-based Multidisciplinary Consensus on Obesity Diagnosis and Treatment" (hereinafter referred to as "Consensus")
.
The "Consensus" mainly includes: obesity epidemiology and pathogenesis, obesity diagnosis and evaluation, clinical intervention and management of obesity, and disease-centric obesity centralized management
.
Through the above four parts, update and optimize the concept of diagnosis and treatment of obesity, in order to reduce the current clinical bias in the diagnosis and treatment of the disease
.
To see the detailed consensus interpretation, please click the link below 👇: Chinese adults are "half fat"! In addition to keeping your mouth open and opening your legs, you also have to know these osteoporosis articles: 5 "Expert Consensus on the Diagnosis and Treatment of Osteoporosis in Primary Medical Institutions (2021)" Osteoporosis is a common type of bone disease in clinical practice.
It is A systemic bone disease characterized by decreased bone mass and destruction of bone tissue microstructure, resulting in increased bone fragility and prone to fractures
.
Because its disease generally has no obvious characteristics, and the degree of clinical diagnosis and treatment is not high, patients often find that they have osteoporosis when they have a fracture.
Therefore, osteoporosis is also called a "quiet killer"
.
Based on this situation, the "Experts Consensus on the Diagnosis and Treatment of Osteoporosis in Primary Medical Institutions (2021)" was officially published in May this year.
Primary medical service institutions, as the most suitable medical institutions for early prevention and treatment of osteoporosis, should have a more unified The prevention and management model and practical and effective guidance standards
.
For this consensus, we mainly introduced the six aspects of osteoporosis screening tools, identification of high-risk groups, clinical diagnosis, treatment goals, prevention and management
.
To see the detailed consensus interpretation, please click the link below 👇: How do the grassroots deal with osteoporosis? Expert consensus is here! Gout: 12 "Gout Treatment Clinical Practice Guidelines in 2021" (APLAR) In recent years, the prevalence of gout has gradually increased in the Asia-Pacific region and even the world
.
According to statistics for 2020, there are more than 80 million people suffering from gout in China, making it the second largest metabolic disease after diabetes
.
In order to better implement standardized treatment of gout and provide clinical medical workers with a basis for diagnosis and treatment decision-making, in December this year, the Asia-Pacific Anti-Rheumatic Alliance (APLAR) released the 2021 clinical practice guidelines for gout treatment, aiming to provide evidence based on existing evidence.
Provide advice on the management of different stages of gout
.
We focused on the interpretation of the guidelines from important issues in gout management such as diet and weight management, non-drug treatment, asymptomatic hyperuricemia treatment, and anti-inflammatory treatment in the acute phase of gout
.
To see the detailed guideline interpretation, please click the link below 👇: Regarding gout, the 18 latest recommendations of clinical practice guidelines are here! Which of the above guidelines/consensus are you most interested in? What other guidelines/consensus interpretations of endocrine diseases do you want to see in the future? Welcome to leave a message at the bottom of the article!
